VRTX Q2 2018 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$752M+38.2% YoY

Gross Profit

$648M86.1% margin

Operating Income

$173M23.0% margin

Net Income

$207M27.6% margin

EPS (Diluted)

$0.80

QoQ Revenue Growth

+17.4%

Cash Flow

Operating Cash Flow

$322M

Free Cash Flow

$292M

Stock-Based Comp.

$82M

Balance Sheet

Total Assets

$4.3B

Total Liabilities

$1.6B

Stockholders' Equity

$2.7B

Cash & Equivalents

$2.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$752M	$544M	+38.2%
Gross Profit	$648M	$473M	+37.0%
Operating Income	$173M	$53M	+228.0%
Net Income	$207M	$18M	+1052.3%

Revenue Segments

ORKAMBI

$311M42%

KALYDECO

$253M34%

SYMDEKO/SYMKEVI

$186M25%

Geographic Segments

UNITED STATES

$585M66%

Non-US

$167M19%

Europe

$136M15%